958 documents

Read All
01:46 , Aug 17, 2018 |  BC Innovations  |  Targets & Mechanisms

Unsaturated remyelination

Enzymes downstream in cholesterol biosynthesis could provide new ways to stimulate remyelination that avoid the baggage of previously identified multiple sclerosis targets, according to a group at Case Western. The university is spinning out Convelo...
Read More
17:02 , Aug 9, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Cellular assays; high throughput screening A high throughput, CRISPR interference (CRISPRi)-based method of mapping genetic interactions could help identify new drug targets for cancer and genetic disorders. The method involves: selecting sgRNAs against genes identified...
Read More
15:41 , Jul 18, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A non-viral CRISPR-Cas9-based method for engineering patient-derived T cells could be used to generate personalized cell therapies for cancer and autoimmune diseases. The method consists of co-electroporating T cells collected from the...
Read More
21:43 , Jul 12, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: June 2018

New Therapeutic Targets and Biomarkers: June 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during June 2018. Therapeutic targets are defined as any protein, gene or other molecule...
Read More
20:51 , Jul 12, 2018 |  BC Extra  |  Preclinical News

Virus-free CRISPR T cell editing

A team led by University of California San Francisco researchers developed a non-viral method to engineer T cell genomes in about one week using CRISPR/Cas9 DNA editing. The method could reduce the time and cost...
Read More
21:41 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Head and neck cancer Cell culture and mouse studies suggest BRD4 inhibitors could help treat cetuximab-resistant squamous cell carcinoma of the head and neck (SCCHN). In two human cetuximab-resistant SCCHN cell lines, cetuximab plus...
Read More
00:59 , Jun 30, 2018 |  BioCentury  |  Regulation

Not a test

Antibiotics developers shouldn’t read too much into FDA’s rejection of the first drug to be reviewed under a new limited-use pathway that is supposed to make it easier to develop treatments for rare and resistant...
Read More
17:52 , Jun 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease; transplant; endocrine/metabolic

INDICATION: Multiple sclerosis (MS); graft-versus-host disease (GvHD); diabetes Cell culture and mouse studies suggest that IL-2 complexed with an anti-IL-2 mAb could help treat GvHD, MS, Type I diabetes and other autoimmune diseases. In human peripheral...
Read More
23:18 , Jun 25, 2018 |  BC Extra  |  Preclinical News

Anti-IL-2 mAb activates Tregs to treat autoimmune diseases

In a paper published in Nature Medicine, scientists generated a human mAb against IL-2 that preferentially activates Tregs and could help treat autoimmune diseases. Previous studies have shown that low doses of IL-2 can help treat...
Read More
16:49 , Jun 21, 2018 |  BC Innovations  |  Translation in Brief

PHIP the script

Cancers lacking key molecular signatures targeted by precision therapies are among the most challenging to treat, but a new study has identified a target, PHIP, for three of those difficult tumor types. A group led...
Read More